The annual meeting of the Health Ministers from the Group of 7 (G7) countries took place from September 11-12, 2016, in Kobe, Japan. The Sabin Vaccine Institute (Sabin) was pleased to see the G7 Health Ministers Kobe Communiqué reiterate a continued emphasis on strengthening efforts to control infectious diseases through international cooperation. As the Health Ministers concluded, “Health is the foundation of human security…We are determined to commit to a healthier world, where all people can receive the basic quality services they need, and are protected from public health threats.”
During my many years as a diplomat, I saw firsthand how the power of collective action can be extraordinarily important in shaping momentous changes. A few examples include: the creation of the PEPFAR program to combat HIV/AIDS, the accelerated response to terrorism following the East African embassy bombings, effective international coordination to tackle the SARS and avian flu threats, and the constructive collaboration between the United States and Vietnam on the issue of Agent Orange.

Sabin Vaccine Institute Partners with King Saud University to Build Vaccine Research and Development Capacity in Saudi Arabia

WASHINGTON, D.C. — June 22, 2016 — The Sabin Vaccine Institute is partnering with King Saud University (KSU) in Riyadh, Saudi Arabia, to advance vaccine research and development capacity in the Middle East and North Africa. As part of the new $6.6 million agreement, Saudi scientists will receive technical training in vaccine development at the Sabin Vaccine Institute Product Development Partnership (Sabin PDP) laboratories in Houston, Texas.

Last year, the leaders of some of the wealthiest nations pledged help control and eliminate the most common neglected tropical diseases (NTDs) by 2020.

Sabin PDP Begins Phase 1 Clinical Trial to Co-Administer Two Novel Hookworm Vaccine Candidates in Brazil

WASHINGTON, D.C. — April 28, 2016 — The Sabin Vaccine Institute (Sabin) today announced that its Product Development Partnership (Sabin PDP) began a Phase 1 clinical trial of Na-APR-1 (M74)/Alhydrogel® co-administered with Na-GST-1/Alhydrogel in Brazilian adults.

This article was originally posted on the DSW Blog.

Photo: Sabin CEO Michael W. Marine, Ambassador (Ret.), with Former President of Ghana, John Kufuor

During the month of October, END7 student supporters are celebrating NTD Success Stories — spreading the exciting news that many countries around the world have already made incredible progress towards the control and elimination of some NTDs. In recent weeks, there have been many new successes to celebrate.

Pages

Subscribe to RSS - Hookworm